Loading...
Loading...
VCEL| Name | Value |
|---|---|
| Revenues | 52.7M |
| Cost of Revenue | 14.4M |
| Gross Profit | 38.2M |
| Operating Expense | 32.2M |
| Operating I/L | 6.1M |
| Other Income/Expense | 0.5M |
| Interest Income | 0.8M |
| Pretax | 6.6M |
| Income Tax Expense | 0.7M |
| Net Income/Loss | 5.9M |
Vericel Corporation is a biopharmaceutical company specializing in cellular therapies for sports medicine and severe burn care markets. The company's autologous cell therapy products include MACI, a solution for knee cartilage defects, and Epicel, a skin replacement treatment for burns. Additionally, the company is developing NexoBrid, a product for eschar removal in burn patients. Vericel generates revenue through the research, development, manufacture, and distribution of these cellular therapies, catering to the needs of patients with specific medical conditions.
